Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays.
PLUVICTO: Every day without progression is a VICTORY
In the PSMAfore trial, men with PSMA+ mCRPC who received PLUVICTO saw more time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy. In that study, 49% of men who received PLUVICTO saw their tumors shrink or disappear (vs 14% with a change in hormone therapy).
Available before chemotherapy for PSMA+ mCRPC**For certain men as determined by their doctor. |
How does targeted treatment work for PSMA+ mCRPC?
Care partners: Find information and materials made for you.
Find downloadable materials with additional information.
Interested in receiving information about PLUVICTO?
PLUVICTO® Pulse is a series of emails that helps you talk to your doctor about PLUVICTO.
mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.